GSK is targeting late 2027 for the commercial launch of Depemokimab, an ultra-long-acting biologic therapy the British drugmaker is developing for chronic inflammatory conditions.
The ultra-long-acting formulation aims to extend dosing intervals beyond current biologic therapies, potentially reducing treatment frequency from weekly or monthly injections to quarterly or longer intervals. Extended-interval biologics represent a growing segment as pharmaceutical companies seek to improve patient adherence and differentiate products in competitive markets.
GSK has prioritised biologics development as part of its strategy to offset patent expirations and compete with specialty pharmaceutical rivals. The company's immunology and respiratory portfolio already includes blockbuster drugs like Nucala for severe asthma, which generated over £1.5 billion in 2023 sales.
Depemokimab's late 2027 timeline suggests GSK is currently in late-stage clinical trials. Phase 3 trial data typically precedes regulatory submissions by 12-18 months, indicating potential filings in 2026 for European Medicines Agency and FDA review.
The biologic therapy market in Europe continues expanding, driven by ageing populations and rising prevalence of chronic inflammatory diseases. Biologics now account for over 30% of pharmaceutical revenues in major European markets, with immunology treatments representing the largest segment.
GSK faces competition from established ultra-long-acting biologics including Amgen's Repatha and Novartis' Cosentyx, both offering extended dosing schedules. Sanofi and AstraZeneca are also advancing long-acting formulations in respiratory and immunology indications.
The 2027 launch target positions Depemokimab to capture market share before potential biosimilar competition intensifies in the 2028-2030 period, when several first-generation biologics lose exclusivity.
GSK's UK research facilities in Stevenage continue to drive the company's biologics pipeline, supported by £1 billion in annual R&D investment focused on immunology, vaccines, and specialty medicines.